BCAX
Bicara Therapeutics Inc. Common Stock
NASDAQ · Healthcare · Biotechnology · US
$23.17
−0.73%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−5.6x
Market Cap
$1.53B
MomentumView details →
1D Return
−0.73%
YTD Return
+37.67%
RSI (14)
40.4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−5.6x
Market Cap
$1.53B
RSI (14)
40.4
MomentumView details →
1D Return
−0.73%
YTD Return
+37.67%
SummaryUpdated Jun 1, 2026
Bicara Therapeutics Inc. (NASDAQ:BCAX) is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Boston, Massachusetts. The company operates as a subsidiary of Biocon Limited, a major Indian biopharmaceutical company. Bicara focuses on developing innovative bifunctional antibody therapies specifically designed to treat solid tumors, representing a novel approach in cancer treatment that combines two therapeutic mechanisms into a single drug molecule.
Similar companies
Latest newsMore news →
Bicara Therapeutics initiated the FORTIFI-FLEX trial, a pivotal Phase III study, and outlined an interim analysis timeline for mid-2027.24d agoBicara Therapeutics announced leadership changes during its Q2 2026 earnings call.24d agoJeremy Bender was appointed as a Class I Director of the Board of Directors and a member of the Audit Committee and Launch Readiness Committee of Bicara Therapeutics Inc., effective July 28, 2026.39d ago